Skip to main content

Week In Review: China Biopharma Books $500 Million Of Deals To Start 2022

AffaMed acquired greater China rights to an ophthalmic drug from Hanmi Pharma in an $145 million agreement. Sperogenix Therapeutics in-licensed China rights to vamorolone from Santhera in a deal valued at up to $124 million, plus royalties
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.